NASDAQ$OVID
Ovid Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Ovid Therapeutics reported its Q1 2025 earnings with a net loss of $10.235 million and total revenue of $0.130 million.
Ovid Therapeutics Inc. reported a net loss of $10.235 million for Q1 2025, an improvement from the $11.694 million loss in Q1 2024. Total revenue for the quarter was $0.130 million, primarily from license and other revenue. The company's cash and cash equivalents stood at $21.136 million, with total assets of $81.654 million.
- Net loss improved to $10.235 million in Q1 2025 from $11.694 million in Q1 2024.
- Total revenue was $0.130 million, consisting solely of license and other revenue.
- Research and development expenses decreased by $3.738 million compared to the prior year, primarily due to the pause of the OV888 (GV101) program and reduced preclinical expenses for OV329.
- General and administrative expenses decreased by $1.147 million due to organizational restructuring and other cost reductions.
- The company's cash, cash equivalents, and marketable securities totaled $43.0 million as of March 31, 2025.
Headline financials
Revenue & EPS history
Ovid Therapeutics · Revenue · Quarterly
$130K
Revenue by segment
Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020
- License and other revenue$5.7M—100.0%
Forward guidance
Ovid Therapeutics expects to continue incurring significant expenses and operating losses for at least the next several years. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund current operating plans through at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q.
Tailwinds
- Continued preclinical and clinical development of drug candidates.
- Building a portfolio of drug candidates through acquisition or in-license.
- Initiating preclinical studies and clinical trials for additional drug candidates.
- Seeking marketing approvals for successful drug candidates.
- Establishing sales, marketing, and distribution infrastructure for commercialization.
Headwinds
- Potential for significant fluctuations in net losses from period to period.
- Uncertainty regarding the timing and costs of clinical trial programs.
- Risk of not achieving profitability due to ongoing operating losses.
- Dependence on additional financing, which may not be available on acceptable terms.
- Potential for delays or termination of drug development efforts if capital is insufficient.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+3.6%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+19.5%
Q2 2024
Best reaction
-26.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.9% | -5.7% | — | |
| Q4 2025 | +14.4% | +26.9% | +44.8% | |
| Q3 2025 | -2.2% | -3.7% | +21.5% | |
| Q1 2025 | -0.7% | -6.2% | -8.2% | |
| Q4 2024 | +0.1% | -11.4% | -48.0% | |
| Q2 2024 | +19.5% | +33.7% | +31.4% | |
| Q1 2024 | +9.9% | +4.3% | +6.0% | |
| Q4 2023 | -7.3% | -11.0% | +2.5% | |
| Q3 2023 | -7.9% | -4.8% | -9.5% | |
| Q2 2023 | -1.8% | -0.6% | +6.6% | |
| Q1 2023 | -5.2% | -2.5% | +0.1% | |
| Q4 2022 | +4.0% | +13.0% | +46.0% | |
| Q3 2022 | +2.1% | +11.1% | +26.4% | |
| Q2 2022 | +0.5% | +2.3% | -1.4% | |
| Q1 2022 | -12.1% | -22.3% | -30.5% | |
| Q4 2021 | -3.4% | +0.3% | +0.3% | |
| Q3 2021 | -2.8% | +0.8% | -9.7% | |
| Q2 2021 | -9.4% | -13.1% | -14.4% | |
| Q1 2021 | +2.3% | +6.9% | +28.4% | |
| Q4 2020 | +4.4% | +9.0% | -6.1% | |
| Q3 2020 | +18.9% | +19.1% | -49.6% | |
| Q2 2020 | -2.4% | +4.3% | -20.4% | |
| Q1 2020 | -0.3% | +10.6% | +43.7% | |
| Q4 2019 | -26.9% | -31.5% | -7.8% | |
| Q3 2019 | -1.5% | -6.5% | +54.2% | |
| Q2 2019 | -2.1% | -5.2% | +11.9% | |
| Q1 2019 | -14.0% | -20.1% | -24.8% | |
| Q4 2018 | -2.0% | +1.0% | -6.1% | |
| Q3 2018 | -8.0% | -7.9% | -39.1% | |
| Q2 2018 | +2.3% | +8.8% | -0.2% | |
| Q1 2018 | +4.8% | -1.9% | -9.5% | |
| Q4 2017 | -13.1% | -11.4% | +35.7% | |
| Q3 2017 | +15.2% | +20.4% | +49.7% | |
| Q2 2017 | -1.6% | +2.8% | +28.0% | |
| Q1 2017 | +5.3% | +0.4% | -29.7% | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro